RxDoctor Payments Data

Sakdhisapol Katanyutanon, MD

Gastroenterology · Waterville, MENPI 1316278898

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 80 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by AbbVie at 58.9% of the total. Reporting peaked in 2024 at $638 and has fallen 65.4% since, to $221 in 2025.

$1,627in general payments, 2019–2025

Across 80 payments — averaging $20.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$959
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$197
  • Johnson & Johnson$190
  • Lilly USA, LLC$150
  • Nestle Healthcare Nutrition Inc.$53
  • Takeda Pharmaceuticals U.S.A., Inc.$52
  • plus $26 from 1 others

What the payments were for

  • Food & beverage$1,627100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,627 in reported general payments places this provider in the 70th percentile of 68 gastroenterology providers in Maine.

See all gastroenterology providers in Maine

Medicare billing

Part B allowed, 2024
$78,266
Medicare patients
333
Services billed
671

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab42$1,165,293
XifaxanRifaximin18$59,536
LinzessLinaclotide22$34,167
VemlidyTenofovir Alafenamide20$30,607
Mesalamine25$17,281
MotegrityPrucalopride Succinate11$13,008
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg626$11,617
Ursodiol23$7,562
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C18$2,594
Balsalazide Disodium13$2,246
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates26$1,560
Omeprazole104$1,230
Esomeprazole Magnesium19$1,081
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl59$1,043
Pantoprazole Sodium61$1,008

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$190$1,165,29342 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu$197$62,13036 claims
AbbVieLinzess$959$34,16722 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$52$13,00811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 68 gastroenterology providers in Maine.

Other gastroenterology in Waterville

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →